TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)

Published:2017-11-21 Issue:64 Volume:8 Page:107621-107629
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Cao Xiaobo¹,Zhao Yang²,Wang Jing²,Dai Bingbing³,Gentile Emanuela¹,Lin Jing¹,Pu Xingxiang⁴,Ji Lin¹,Wu Shuhong¹,Meraz Ismail¹,Majidi Mourad¹,Roth Jack A.¹

Affiliation:

1. Department of Thoracic and Cardiovascular Surgery, Section of Thoracic Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

2. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

3. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

4. Department of Thoracic Medical Oncology, Hunan Cancer Hospital, Changsha, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model;2024-07-09

2. NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model;2024-07-09

3. NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model;2024-03-28

4. Immunohistochemical and molecular evaluation of TUSC2 expression in breast cancer;Molecular Biology Reports;2024-03-06

5. From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer;Frontiers in Immunology;2024-02-15